-$0.17 Earnings Per Share Expected for DexCom, Inc. (DXCM) This Quarter

Equities research analysts forecast that DexCom, Inc. (NASDAQ:DXCM) will report ($0.17) earnings per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for DexCom’s earnings. The highest EPS estimate is $0.18 and the lowest is ($0.60). DexCom posted earnings of ($0.32) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 46.9%. The firm is scheduled to report its next quarterly earnings results on Wednesday, May 1st.

On average, analysts expect that DexCom will report full-year earnings of $0.46 per share for the current fiscal year, with EPS estimates ranging from ($0.16) to $0.79. For the next year, analysts forecast that the firm will report earnings of $0.94 per share, with EPS estimates ranging from $0.52 to $1.38. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover DexCom.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.38. The firm had revenue of $338.00 million during the quarter, compared to analysts’ expectations of $331.60 million. DexCom had a negative net margin of 12.32% and a positive return on equity of 5.42%. The firm’s revenue for the quarter was up 52.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share.

Several research analysts recently issued reports on DXCM shares. Cowen increased their price target on shares of DexCom from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Friday, February 22nd. Morgan Stanley increased their price target on shares of DexCom from $135.00 to $160.00 and gave the stock an “equal weight” rating in a report on Monday, February 25th. BidaskClub cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Canaccord Genuity increased their price target on shares of DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, February 22nd. Finally, Piper Jaffray Companies increased their price target on shares of DexCom to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, January 9th. Seven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. DexCom presently has an average rating of “Buy” and a consensus price target of $149.53.

NASDAQ DXCM traded up $0.17 during trading hours on Monday, hitting $143.24. 740,961 shares of the stock were exchanged, compared to its average volume of 1,281,315. The stock has a market capitalization of $12.73 billion, a P/E ratio of 477.47 and a beta of 0.84. DexCom has a 12-month low of $58.78 and a 12-month high of $156.16. The company has a quick ratio of 4.43, a current ratio of 4.71 and a debt-to-equity ratio of 0.60.

In other DexCom news, EVP Steven Robert Pacelli sold 3,114 shares of the company’s stock in a transaction dated Friday, December 21st. The shares were sold at an average price of $109.41, for a total transaction of $340,702.74. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 11,162 shares of the company’s stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $121.67, for a total transaction of $1,358,080.54. The disclosure for this sale can be found here. Insiders have sold 51,388 shares of company stock worth $6,867,204 over the last 90 days. 1.80% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $13,436,000. Norges Bank acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $107,191,000. Dimensional Fund Advisors LP grew its position in shares of DexCom by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 164,763 shares of the medical device company’s stock valued at $19,738,000 after purchasing an additional 3,468 shares during the last quarter. Equitable Trust Co. grew its position in shares of DexCom by 2.4% in the fourth quarter. Equitable Trust Co. now owns 6,500 shares of the medical device company’s stock valued at $779,000 after purchasing an additional 150 shares during the last quarter. Finally, Nordea Investment Management AB acquired a new stake in shares of DexCom in the fourth quarter valued at approximately $441,000.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Bollinger Bands

Get a free copy of the Zacks research report on DexCom (DXCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply